Release date: 2017-03-09 First, the genetic basis of the tumor The genetic basis of tumors is the cornerstone of modern cancer research. As early as the early 20th century, scientists discovered that abnormal mitosis and malignant tumors are involved in cells. In the actual mid-leaf, the discovery of DNA double helix structure clarified the genetic mechanism of genetic material. Scientists further found that in cancer cells, chromosomal instability can promote chromosomal abnormalities and mutation accumulation. As the research progresses, a hypothesis is accepted by more and more researchers: chromosomal abnormalities and genomic instability are the initiating factors of cancer. Second, tumor immunity Tumor immune escape and corresponding treatment have become hotspots in immunology research in recent years. In fact, as early as 1909, some scientists suggested that in cancer cells, the carcinogenic pattern of mutation accumulation and alteration enables the immune system to destroy cancer cells like inflammatory substances, and the immune system can inhibit the development of tumors. In drug research, until 2010, the dendritic cell vaccine sipuleucel-T for advanced prostate cancer became the first cancer vaccine approved by the US Food and Drug Administration (FDA). In 2011, anti-CTLA4 drug Iplimma was approved by the US Food and Drug Administration (FDA) as a new treatment for advanced melanoma, and its role was further verified. This is a groundbreaking moment in the field of cancer immunotherapy. Third, the virus and tumor The relationship between viruses and cancer is a hot spot in cancer research. In 1910, scientist Peyton Rous discovered a spindle cell sarcoma on a hen and identified the Russ sarcoma virus RSV. At that time, his important findings were not taken seriously until 1966, when he was 77, Rous won the Nobel Prize for the study. In 1969, scientists Robert Huebner and George Todaro began a series of studies that believed that most cancers were caused by retroviral gene expression. It seems that their views are not entirely correct, but they have brought a lot of inspiration to other discoveries in the field of cancer. Fourth, hormones and tumors Hormones can affect the development of cancer, and we are generally accepted. However, it has been a hundred years since the earliest observation that hormones are beneficial to some cancer patients to develop the first drug targeting endocrine organs. Fifth, cancer stem cells Cancer stem cells are still a hot topic of research today. In 1937, Uacob Furth first mentioned the cancer stem cells (CSC). At the time, there was controversy about whether leukemia originated from viruses or cells, but they first invented quantitative methods to measure clonal potential. Until 1994, John Dick and colleagues isolated and purified the CSC. Current research on solid tumors has made the concept of CSC no longer limited to hematopoietic malignancies. The isolation of solid tumor stem cells has made researchers more convinced that the target of cancer treatment is not a mixed population of tumor cells, but a small number of CSCs with self-renewal capabilities. Currently, we are working hard to clarify the regulatory mechanisms of CSC. Six, angiogenesis and tumor The relationship between angiogenesis and tumors has been a research hotspot. In 1939, Gordon Ide and his colleagues discovered that weight may produce an angiogenic stimulating substance when studying the blood vessels around the tumor. In 1945, Glenn Algire et al. conducted a more in-depth study on kinetics and found that tumors could not grow effectively in the absence of blood supply. Therefore, tumors can be treated by inhibiting the blood supply system. In practical applications, until 2004, the US Food and Drug Administration approved bevacizumab to treat metastatic colorectal cancer. Seven, tumor suppressor gene Tumor suppressor genes are now frequently found in various literatures. In the 1970s and the end of 1980, oncogenes were the mainstream of cancer research, and mutations were the cause of tumors. In 1973, Savid Comings proposed the hypothesis that tumor suppressor genes are present in tumors. However, after a decade of technology developed to the molecular level, Webster Cavanee et al first identified two tumor suppressor genes, RB and p53. Today we know that tumor suppressor genes and oncogenes are opposite poles, but it took decades to get this recognition. Eight, apoptosis and tumor Apoptosis and tumors are now also research hotspots. In 1972, Johen Kerr and Andrew Wyllie discovered that the phenomenon of cell apoptosis began to study the special phenomenon of cell death, and that apoptosis is different from necrosis, which is a normal process of suicide. The tumor suppressor gene p53 can induce apoptosis, which further supports the mechanism by which apoptosis is a limiting tumor. A series of findings suggest that induction of apoptosis fails to produce hyperplasia, whereas further mutations result in significant tumor formation. Nine, tumor microenvironment The study of tumor microenvironment has become hotter in recent years. In 1975, Beatrice Mintz and Karl Illmensee found that tumor cells can develop into various types of cells in a suitable environment and can be restored to normal cells. At the same time, they also speculated that the initial stage of tumorigenesis may not involve mutations. Ten years later, we began to study how the environmental and inflammatory infection processes affect tumorigenesis at the molecular level. But until today, there are still many problems in this field that have not been clarified, and there are still high-level articles published. X. Epigenetics of tumors In the early 1980s, the tumor field was confusing about the mutations in oncogenes associated with tumors. The mutation of the Rans oncogene was discovered in 1982, which changed its biological function, but this is very controversial. In this environment, epigenetic changes are ignored in many areas. Studies in the 1980s showed that both oncogenes and tumor suppressor genes can undergo epigenetic changes, which ultimately led us to make epigenetic changes now an important indicator of diagnosis and treatment. A large number of mouse models studied the effects of methylation and found that tumor suppressors are hypermethylated in tumors and silenced, but this methylation can be re-removed by DNA methylase inhibitors. Some DNA methylase inhibitors have been used in clinical cancer treatment, but the therapeutic effect is still controversial. Regardless, DNA methylation reversal is a new strategy for treating tumors. In fact, in addition to these ten directions, cancer research has important areas such as cell cycle and DNA damage checkpoints, mechanisms of tumor genetic instability, and tumor-targeted therapy. There are still many problems to be clarified. Source: bio360 (micro signal bio360)
Our super green powder are mainly used as food supplement, health and wellness product additive, you can mix the super greens and Vegetable Powder according to your own formula. Spirulina, chlorella, broccoli powder, kale powder, buckwheat powder, wheatgrass powder, barley grass powder. Those powders are rich in protein, fibers, antioxidant and chlorophyll which can clear free radicals, enhance immunity and providing trace elements people can`t obtain from high carbohydrate diet. Organic super greens powders are Non-GMO, gluten free and vegan friendly, welcome to reach us for more you would like to know.
Super Greens,Buckwheat Grass,Organic Super Greens,Super Greens Powder YT(Xi'an) Biochem Co., Ltd. , https://www.ytnutra.com